title: NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.
authors.forename: Matthew
authors.initials: M
authors.lastname: Dyer
authors.forename: Joanna
authors.initials: J
authors.lastname: Richardson
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.forename: Jane
authors.initials: J
authors.lastname: Adam
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000592:standards / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D019057:Quality-Adjusted Life Years; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel